Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 12Pancreatic Neoplasms 6Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Leukemia 4Colorectal Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Radiodermatitis 2Neoplasms by Site 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Communication 2Carcinoma, Transitional Cell 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9Paclitaxel 8pembrolizumab 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Albumin-Bound Paclitaxel 6Pemetrexed 4Nivolumab 4Irinotecan 4Everolimus 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2vosaroxin 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × Standard of Care × Clear all
NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Daiichi Sankyo

Phase 2 Completed
233 enrolled 26 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡